BACKGROUND: The efficacy of carboplatin, irinotecan, and bevacizumab among recurrent glioblastoma (GBM) patients after prior progression on bevacizumab therapy in a phase 2, open-label, single-arm trial was evaluated. METHODS: Eligible patients received carboplatin (area under the plasma curve [AUC] 4 mg/ml-min) on day 1, whereas bevacizumab (10 mg/kg) and irinotecan (340 mg/m(2) for patients on CYP3A enzyme-inducing anti-epileptics [EIAEDs] and 125 mg/m(2) for patients not on EIAEDs) were administered on days 1 and 14 of every 28-day cycle. Patients were evaluated after each of the first 2 cycles and then after every other cycle. Treatment continued until progressive disease, unacceptable toxicity, noncompliance, or voluntary withdrawal. The primary end point was progression-free survival at 6 months (PFS-6), and secondary end points included safety and median overall survival (OS). RESULTS: All patients had progression on at least 1 prior bevacizumab regimen and 56% enrolled after either second or third overall progression. The median OS was 5.8 months (95% confidence interval [CI], 4.0-7.0 months) and PFS-6 rate was 16% (95% CI, 5.0%-32.5%). The most common grade 3 or 4 events were hematologic and occurred in 29% of cycles. Nine patients (38%) required dose modification. There were no treatment-related deaths. CONCLUSIONS: Carboplatin, irinotecan, and bevacizumab was associated with modest activity and adequate safety among recurrent GBM patients who progressed on bevacizumab previously.
BACKGROUND: The efficacy of carboplatin, irinotecan, and bevacizumab among recurrent glioblastoma (GBM) patients after prior progression on bevacizumab therapy in a phase 2, open-label, single-arm trial was evaluated. METHODS: Eligible patients received carboplatin (area under the plasma curve [AUC] 4 mg/ml-min) on day 1, whereas bevacizumab (10 mg/kg) and irinotecan (340 mg/m(2) for patients on CYP3A enzyme-inducing anti-epileptics [EIAEDs] and 125 mg/m(2) for patients not on EIAEDs) were administered on days 1 and 14 of every 28-day cycle. Patients were evaluated after each of the first 2 cycles and then after every other cycle. Treatment continued until progressive disease, unacceptable toxicity, noncompliance, or voluntary withdrawal. The primary end point was progression-free survival at 6 months (PFS-6), and secondary end points included safety and median overall survival (OS). RESULTS: All patients had progression on at least 1 prior bevacizumab regimen and 56% enrolled after either second or third overall progression. The median OS was 5.8 months (95% confidence interval [CI], 4.0-7.0 months) and PFS-6 rate was 16% (95% CI, 5.0%-32.5%). The most common grade 3 or 4 events were hematologic and occurred in 29% of cycles. Nine patients (38%) required dose modification. There were no treatment-related deaths. CONCLUSIONS:Carboplatin, irinotecan, and bevacizumab was associated with modest activity and adequate safety among recurrent GBMpatients who progressed on bevacizumab previously.
Authors: Patrick Y Wen; David R Macdonald; David A Reardon; Timothy F Cloughesy; A Gregory Sorensen; Evanthia Galanis; John Degroot; Wolfgang Wick; Mark R Gilbert; Andrew B Lassman; Christina Tsien; Tom Mikkelsen; Eric T Wong; Marc C Chamberlain; Roger Stupp; Kathleen R Lamborn; Michael A Vogelbaum; Martin J van den Bent; Susan M Chang Journal: J Clin Oncol Date: 2010-03-15 Impact factor: 44.544
Authors: Axel Grothey; Mary M Sugrue; David M Purdie; Wei Dong; Daniel Sargent; Eric Hedrick; Mark Kozloff Journal: J Clin Oncol Date: 2008-10-14 Impact factor: 44.544
Authors: Kathleen R Lamborn; W K Alfred Yung; Susan M Chang; Patrick Y Wen; Timothy F Cloughesy; Lisa M DeAngelis; H Ian Robins; Frank S Lieberman; Howard A Fine; Karen L Fink; Larry Junck; Lauren Abrey; Mark R Gilbert; Minesh Mehta; John G Kuhn; Kenneth D Aldape; Janelle Hibberts; Pamela M Peterson; Michael D Prados Journal: Neuro Oncol Date: 2008-03-04 Impact factor: 12.300
Authors: Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff Journal: Lancet Oncol Date: 2009-03-09 Impact factor: 41.316
Authors: Gigi Chen; Minh Huynh; Lou Fehrenbacher; Howard West; Primo N Lara; Leonid L Yavorkovsky; Michael Russin; Desiree Goldstein; David Gandara; Derick Lau Journal: J Clin Oncol Date: 2009-02-09 Impact factor: 44.544
Authors: Teri N Kreisl; Lyndon Kim; Kraig Moore; Paul Duic; Cheryl Royce; Irene Stroud; Nancy Garren; Megan Mackey; John A Butman; Kevin Camphausen; John Park; Paul S Albert; Howard A Fine Journal: J Clin Oncol Date: 2008-12-29 Impact factor: 44.544
Authors: Marta Santisteban; Jan C Buckner; Joel M Reid; Wenting Wu; Bernd W Scheithauer; Matthew M Ames; Sara J Felten; Daniel A Nikcevich; Martin Wiesenfeld; Kurt A Jaeckle; Evanthia Galanis Journal: J Neurooncol Date: 2008-12-10 Impact factor: 4.130
Authors: David A Reardon; Annick Desjardins; Katherine B Peters; Sridharan Gururangan; John H Sampson; Roger E McLendon; James E Herndon; Anuradha Bulusu; Stevie Threatt; Allan H Friedman; James J Vredenburgh; Henry S Friedman Journal: J Neurooncol Date: 2011-10-11 Impact factor: 4.130
Authors: G Simonetti; E Trevisan; A Silvani; P Gaviani; A Botturi; E Lamperti; D Beecher; L Bertero; C Bosa; A Salmaggi Journal: Neurol Sci Date: 2013-11-27 Impact factor: 3.307
Authors: Antonio Omuro; Timothy A Chan; Lauren E Abrey; Mustafa Khasraw; Anne S Reiner; Thomas J Kaley; Lisa M Deangelis; Andrew B Lassman; Craig P Nolan; Igor T Gavrilovic; Adilia Hormigo; Cynthia Salvant; Adriana Heguy; Andrew Kaufman; Jason T Huse; Katherine S Panageas; Andreas F Hottinger; Ingo Mellinghoff Journal: Neuro Oncol Date: 2012-12-14 Impact factor: 12.300